MOUSE INTERLEUKIN-12 (IL-12) P40 HOMODIMER - A POTENT IL-12 ANTAGONIST

被引:418
作者
GILLESSEN, S
CARVAJAL, D
LING, P
PODLASKI, FJ
STREMLO, DL
FAMILLETTI, PC
GUBLER, U
PRESKY, DH
STERN, AS
GATELY, MK
机构
[1] HOFFMANN LA ROCHE INC,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110
[2] HOFFMANN LA ROCHE INC,DEPT BIOTECHNOL,NUTLEY,NJ 07110
关键词
INTERLEUKIN; INTERLEUKIN-12; P40; SUBUNIT; ANTAGONIST;
D O I
10.1002/eji.1830250133
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukin-12 (IL-12) is a cytokine that has regulatory effects on T and natural killer (NK) cells and is composed of two disulfide-bonded subunits, p40 and p35. It was recently reported that supernatants from cultures of mouse IL-12 (moIL-12) p40-transfected COS cells could inhibit IL-12-dependent responses in vitro (Mattner, F., et al., Eur. J. Immunol. 1993. 23: 2202). We have further characterized the nature of the inhibitory substance. Purified mouse p40 produced in a baculovirus expression system was found to consist of two species: the p40 monomer and a disulfide-linked p40 dimer [(p40)(2)]. The (p40)(2) was 25- to 50-fold more active than the p40 monomer in causing specific, dose-dependent inhibition of IL-12-induced mouse concanavalin A (Con A) blast proliferation and could also inhibit IL-12-induced interferon-gamma (IFN-gamma) secretion by mouse splenocytes and IL-12-dependent activation of mouse NK cells. Competitive binding studies on mouse Con A blasts showed that (p40)(2) was equally effective as moIL-12 in competing with I-125-labeled moIL-12 ([I-125]moIL-12) for binding to mouse Con A blasts. However, in contrast to moIL-12, mouse (p40)(2) displayed little ability to compete with I-125-labeled human IL-12 (huIL-12) for binding to high-affinity IL-12 receptors (IL-12R) on human phytohemagglutinin (PI-IA) blasts and caused little or no inhibition of huIL-12-induced human PHA blast proliferation. Nonetheless, mouse (p40)(2) was equally effective as moIL-12 in competing with [I-125]huIL-12 for binding to COS cells transfected with the human IL-12R beta subunit and expressing low-affinity IL-12 binding sites. These results suggest that (i) the majority of the structural determinants required for binding of IL-12 to its receptor are contained within the p40 subunit, but p35 is required for signaling, (ii) the p40 subunit of 11,-12 interacts with the beta subunit of IL-12R, and (iii) (p40)(2) may be a suitable IL-12 antagonist for studying the role of IL-12 in various immune responses in vice as well as in vitro. Further studies are required to determine whether or not (p40)(2) is produced by normal lymphoid cells and is a physiologic regulator of IL-12 activity.
引用
收藏
页码:200 / 206
页数:7
相关论文
共 31 条
[1]   INDUCTION OF INTERFERON-GAMMA PRODUCTION BY NATURAL-KILLER-CELL STIMULATORY FACTOR - CHARACTERIZATION OF THE RESPONDER CELLS AND SYNERGY WITH OTHER INDUCERS [J].
CHAN, SH ;
PERUSSIA, B ;
GUPTA, JW ;
KOBAYASHI, M ;
POSPISIL, M ;
YOUNG, HW ;
WOLF, SF ;
YOUNG, D ;
CLARK, SC ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (04) :869-879
[2]  
CHIZZONITE R, 1992, J IMMUNOL, V148, P3117
[3]  
CHIZZONITE R, 1991, J IMMUNOL, V147, P1548
[4]  
CHUA AO, 1994, J IMMUNOL, V153, P128
[5]   PRODUCTION OF NATURAL-KILLER-CELL STIMULATORY FACTOR (INTERLEUKIN-12) BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS [J].
DANDREA, A ;
RENGARAJU, M ;
VALIANTE, NM ;
CHEHIMI, J ;
KUBIN, M ;
ASTE, M ;
CHAN, SH ;
KOBAYASHI, M ;
YOUNG, D ;
NICKBARG, E ;
CHIZZONITE, R ;
WOLF, SF ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1387-1398
[6]  
GATELY MK, 1991, J IMMUNOL, V147, P874
[7]   REGULATION OF HUMAN CYTOLYTIC LYMPHOCYTE-RESPONSES BY INTERLEUKIN-12 [J].
GATELY, MK ;
WOLITZKY, AG ;
QUINN, PM ;
CHIZZONITE, R .
CELLULAR IMMUNOLOGY, 1992, 143 (01) :127-142
[8]   ADMINISTRATION OF RECOMBINANT IL-12 TO NORMAL MICE ENHANCES CYTOLYTIC LYMPHOCYTE ACTIVITY AND INDUCES PRODUCTION OF IFN-GAMMA IN-VIVO [J].
GATELY, MK ;
WARRIER, RR ;
HONASOGE, S ;
CARVAJAL, DM ;
FAHERTY, DA ;
CONNAUGHTON, SE ;
ANDERSON, TD ;
SARMIENTO, U ;
HUBBARD, BR ;
MURPHY, M .
INTERNATIONAL IMMUNOLOGY, 1994, 6 (01) :157-167
[9]  
GATELY MK, 1982, J NATL CANCER I, V69, P1245
[10]  
GATELY MK, 1992, CURRENT PROTOCOLS IM, V1